A Study of OV101 in Individuals With Fragile X Syndrome
Public ClinicalTrials.gov record NCT03697161. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome
Study identification
- NCT ID
- NCT03697161
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Healx AI
- Industry
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- OV101 (gaboxadol) Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years to 22 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2018
- Primary completion
- Feb 2, 2020
- Completion
- Feb 25, 2020
- Last update posted
- Jan 22, 2024
2018 – 2020
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ovid Therapeutics Investigative Site | Sacramento | California | 95817 | — |
| Ovid Therapeutics Investigative Site | Aurora | Colorado | 80045 | — |
| Ovid Therapeutics Investigative Site | Chicago | Illinois | 60612 | — |
| Ovid Therapeutics Investigative Site | Baltimore | Maryland | 21205 | — |
| Ovid Therapeutics Investigative Site | Cincinnati | Ohio | 45229 | — |
| Ovid Therapeutics Investigative Site | Nashville | Tennessee | 37212 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03697161, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03697161 live on ClinicalTrials.gov.